Central corneal thickness during treatment with travoprost 0.004% in glaucoma patients

Journal of Ocular Pharmacology and Therapeutics

Volumn 25, Issue 5, 2009, Pages 459-462

  Schlote, Torsten ^a   Tzamalis, Argyrios ^b   Kynigopoulos, Myron ^b  

^a Outpatient Clinic of Ophthalmology Ambimed   (Switzerland)

^b Clinic Pallas   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TRAVOPROST;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORNEA THICKNESS; DRUG EFFECT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; TOPICAL TREATMENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CLOPROSTENOL; CORNEA; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; OCULAR HYPERTENSION; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TONOMETRY, OCULAR;

EID: 70350447793     PISSN: 10807683     EISSN: None     Source Type: Journal    
DOI: 10.1089/jop.2009.0007     Document Type: Article

References (22)

1. Al-Jazzaf, A.M., DeSantis, L., and Netland, P.A. Travoprost: A potent ocular hypotensive agent. Drugs Today (Barc.). 39:61-74, 2003.
2. Huang, P., Zhong, Z., Wu, L., et al. Increased iridal pigmentation in Chinese eyes after use of travoprost 0.004%. J. Glaucoma. 18:153-156, 2009.
3. Netland, P.A., Landry, T., Sullivan, E.K., et al.; Travoprost Study Group. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am. J. Ophthalmol. 132:472-484, 2001.
4. Lim, K.S., Nau, C.B., O'Byrne, M.M., et al. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 115:790-795, 2008.
5. Sharif, N.A., Kelly, C.R., and Crider, J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 44:715-721, 2003.
6. Toris, C.B., Gabelt, B.T., and Kaufmann, P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 53(Suppl 1):S107-S120, 2008.
7. Lindsey, J.D., Kashiwagi, K., Boyle, D., et al. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15:869-875, 1996.
8. Weinreb, R.N., and Lindsey, J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:716-722, 2002.
9. Ocklind, A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp. Eye Res. 67:179-191, 1998.
10. Sagara, T., Gaton, D.D., Lindsey, J.D., et al. Topical prostaglandin F2alpha treatment reduces collagen types I, III, and IV in the monkey uveoscleral outfl ow pathway. Arch Ophthalmol. 117:794-801, 1999.
11. Schlötzer-Schrehardt, U., Zenkel, M., and Nüsing, R.M. Expression and localisation of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis. Sci. 43:1475-1487, 2002.
12. Mietz, H., Esser, J.M., Welsandt, G., et al. Latanoprost stimulates secretion of matrix metalloproteinases in tenon fi broblasts both in vitro and in vivo. Invest. Ophthalmol. Vis. Sci. 44:5182-5188, 2003.
13. Weinreb, R.N., Lindsey, J.D., Marchenko, G., et al. Prostaglandin FP agonists alter metalloproteinase gene expression in sclera. Inv. Ophthalmol. Vis. Sci. 45:4368-4377, 2004.
14. Liu, Y., Yanai, R., Lu, Y., et al. Effects of antiglaucoma drugs on collagen gel contraction mediated by human corneal fi broblasts. J. Glaucoma. 15:255-259, 2006. (Pubitemid 43916820)
15. Wu, K.Y., Wang, H.Z., and Hong, S.J. Effect of latanoprost on cultured porcine corneal stromal cells. Curr. Eye Res. 30:871-879, 2005.
16. Viestenz, A., Martus, P., Schlötzer-Schrehardt, U., et al. Impact of prostaglandin-F(2alpha)-analogues and carbonic anhydrase inhibitors on central corneal thickness-a cross-sectional study on 403 eyes. Klin. Monatsbl. Augenheilkd. 22:753-756, 2004.
17. Airiani, S., Trokel, S.L., Lee, S.M., et al. Evaluating central corneal thickness measurements with noncontact optical lowcoherence refl ectometry and contact ultrasound pachymetry. Am. J. Ophthalmol. 142:164-165, 2006.
18. Arcieri, E.S., Pierre Filho, P.T., Wakamatsu, T.H., et al. The effects of prostaglandin analogues on the blood aqueous barrier and corneal thickness of phakic patients with primary open-angle glaucoma and ocular hypertension. Eye. 22:179-183, 2008.
19. Sen, E., Nalcacioglu, P., Yazici, A., et al. Comparison of the effects of latanoprost and bimatoprost on central corneal thickness. J. Glaucoma. 17:398-402, 2008.
20. Hatanaka, M., Vessani, R.M., Elias, I.R., et al. The effect of prostaglandin analogs and prostamide on central corneal thickness. J. Ocul. Pharmacol. Ther. 25:51-53, 2009.
21. Lass, J.H., Khosrof, S.A., Laurence, J.K., et al. A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 116:1003-1010, 1998.
22. Spörl, E., Terai, N., Haustein, M., et al. Biomechanical condition of the cornea as a new indicator for pathological and structural changes. Ophthalmologe. 106:512-520, 2009.